Skip to main content

Post-IPO Debt Therapeutics Companies

Explore 28 therapeutics startups that raised post-ipo debt funding. Access verified founder contact information and fundraising data.

Total Companies
28
Total Funding
$5.0B
Avg Funding
$200.2M
Cities
15

Export 28 Post-IPO Debt Therapeutics Companies

Get founder emails, funding data, and company details in one CSV

Start Free Trial

Recently Funded Companies

Export
Ansager, Denmark
$315K
raised

Dancann Pharma manufactures medical cannabis and develops novel cannabinoid therapeutics for a broad range of diseases.

Jul 2025
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

New York, United States
$125.0M
raised

MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.

Jul 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

South San Francisco, United States
$50.0M
raised

Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.

Jul 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Alpharetta, United States
$3.0M
raised

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

Jul 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$105.0M
raised

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.

Jul 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 28 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Hamel, United States
$500.0M
raised

Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.

Jun 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Newton, United States
$1.0M
raised

Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for patients with serious rare diseases.

Jun 2023
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

San Francisco, United States
$10.0M
raised

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

Jun 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Lund, Sweden
$644K
raised

ChemoTech is an innovator in gentle cancer treatment and effective pain management.

Jun 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

San Francisco, United States
$1.3B
raised

Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders.

May 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 28 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
South San Francisco, United States
$10.0M
raised

Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for cancer.

May 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

New York, United States
$570.0M
raised

Axsome Therapeutics is a biopharmaceutical company that develops therapies for the management and treatment of neurological disorders.

May 2025
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Foster City, United States
$600.0M
raised

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

May 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Newton, United States
$6.0M
raised

TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.

Apr 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$20.0M
raised

Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.

Apr 2022
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 28 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
San Diego, United States
$9.7M
raised

Irras is a commercial-stage medical technology company.

Apr 2023
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Menlo Park, United States
$10.0M
raised

Forum Markets developing novel drugs for treating distinct inflammatory diseases.

Mar 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$100.0M
raised

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Mar 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

La Jolla, United States
$75.0M
raised

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Mar 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$550.0M
raised

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

Mar 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 28 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Cambridge, United States
$100.0M
raised

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Feb 2026
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

San Francisco, United States
$200.0M
raised

Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.

Dec 2025
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Florham Park, United States
$10.0M
raised

Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.

Dec 2025
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

South San Francisco, United States
$300.0M
raised

GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.

Dec 2021
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Redwood City, United States
$350.0M
raised

Guardant Health is a precision oncology company that uses blood tests, data sets, and analytics to provide treatment to cancer patients.

Nov 2025
Post-IPO Debt

Founder Contacts

41,000+ verified contacts

Showing 1 to 25 of 28 companies

Ready to Connect with Post-IPO Debt Therapeutics Startups?

Get verified founder emails, funding details, and company data for 28 post-ipo debt therapeutics companies.

Get Started - Access Contact Information

Join thousands of sales teams, investors, and service providers using VCBacked